Brief: Resverlogix provides groundbreaking results in patients with severe kidney impairments
23/01/2017 12:03
Jan 23 (Reuters) - Resverlogix Corp RVX.TO
* Announced preliminary results from New Zealand based Phase
1 trial with severe kidney (renal) impaired patients
Source text for Eikon: ID:nCNWSC5Cma
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment